Formal regulations are struggling to keep up with the breakneck speed of AI innovation. Consequently, the actual standards for AI governance will emerge organically from industry best practices, born from incident responses and cutting-edge research. These practical solutions will be adopted long before they are codified into law.

Acknowledging their safety plans might be inadequate, leaders from multiple frontier labs have begun to seriously entertain a coordinated slowdown. This represents a major shift, as they also explore legal "safe harbors" to collaborate on safety without triggering antitrust violations, breaking the frame of the current race.

Healthcare is a model for AI governance beyond its regulatory framework. The industry has a pre-existing infrastructure of trust, experience with diverse use cases, established practices for post-deployment monitoring, and a deep understanding of human-in-the-loop systems, all directly applicable to AI.

Leaders from Anthropic and DeepMind have voiced support for creating a self-regulatory organization (SRO) for AI, modeled after the financial industry's FINRA. Such a body could establish standards and enforce rules more quickly than government, with real power to decertify non-compliant companies.

Major AI companies are not solely seeking to stifle competition with regulation. They are also signaling an inability to self-regulate amidst intense competitive pressure, effectively asking external bodies to impose a mandatory safety floor that applies to everyone.

The debate over AI regulation often gets bogged down in technical complexity. A simpler, powerful argument is that nearly every other impactful technology—from cars and planes to food and medicine—requires pre-market safety validation. AI, with its greater potential risks, should be no different.

AI expert Max Tegmark argues that regulation, like the FDA for pharma, would shift incentives. Instead of a 'race to the bottom' on unchecked capabilities, companies would compete to be first to develop provably safe AI. This would create a golden age of innovation in areas like medicine while sidelining riskier applications.

To ensure AI safety without waiting for regulation, Musk suggests that major AI labs (including those in China) should test each other's models pre-release. This creates a competitive incentive to find flaws and raises public alarm if a dangerous model is released, leveraging public opinion and legal liability as enforcement.

An FDA-style regulatory model would force AI companies to make a quantitative safety case for their models before deployment. This shifts the burden of proof from regulators to creators, creating powerful financial incentives for labs to invest heavily in safety research, much like pharmaceutical companies invest in clinical trials.